Neomera’s Integrated Approach to AI Drug Discovery
Generative AI is revolutionizing drug discovery, promising to design biologics, small molecules, nucleic acids, and more that target proteins with precision. It’s thrilling, AI models can generate thousands of potential drug hits with blazing speed, igniting dreams of cures for every disease. But here’s the reality check: most of these hits fizzle out during experimental validation, forcing the process to restart. Why? Because biology governs the human body, and current AI prediction models alone rarely make the leap to preclinical success. At Neomera, we bridge this gap. Our platform fuses AI’s power with experimental validation, delivering target-specific, wet lab-tested hits backed by our unique training dataset. This approach boosts the odds of creating real drug candidates in just weeks. Here’s how we’re different and why it works.
Start with Biology
At Neomera, we invested significant effort into integrating novel experimental platforms capable of screening drug candidates against almost all kinds of protein targets, including challenging ones such as membrane-bound receptors. We begin with high-throughput biological screening designed for exceptional efficiency, evaluating tens to hundreds of millions of hits in mere days. This rapid approach generates a wealth of binding data, revealing how each hit interacts with disease targets. Unlike traditional methods that drag on for months even years, our platform delivers actionable insights within weeks, enabling us to identify promising molecules with unmatched speed and efficiency. This screening platform is the foundation of our ability to tackle complex diseases effectively.
Our Data Moat
Our edge lies in the unique training data we create. By sequencing every hit from our high-throughput screens using next-generation sequencing (NGS), we capture the full spectrum of binding behaviors, strong, weak, and everything in between. Unlike public datasets that highlight only positive hits, our comprehensive data includes negative and neutral binding interactions, enriching the training set for our AI models. This unparalleled dataset enhances prediction accuracy and builds a competitive advantage, setting Neomera apart in drug discovery.
Experimentally Validated Drug Hits with Tailored AI Model
While many emphasize the size and complexity of algorithms, we believe that the most effective AI model is one that is tailored to fit the data. Our proprietary AI model is designed to analyze this data and pinpoint target-specific candidates. It not only identifies high-potential hits but also uncovers the amino acid motifs driving their specificity. Unlike de novo AI designs that require post-hoc validation, our platform integrates experimental testing with AI optimization from the start. The result is a pipeline of lab-validated hits, ready to advance toward treatments for diseases like chronic pain, addiction, and beyond, delivered with precision and speed.
Scaling Real World Application
Our current flagship program is developing highly specific non-opioid treatments for chronic pain, addressing a massive health crisis. But Neomera’s vision extends far beyond, we’re building a platform that effortlessly scales to tackle many unmet clinical needs like addiction, fibrosis, endometriosis, and more. Our biological validation goes beyond target specificity; by pairing it with advanced functional screening assays, we optimize for critical drug properties such as blood-brain barrier penetration, enhanced pharmacokinetics, and stability. This holistic approach increases our candidates’ chances of success in preclinical and clinical stages, paving the way for transformative therapies across diverse diseases.
A Future Where AI and Biology Dance Together
At Neomera, we believe the future of drug discovery lies in the seamless integration of AI and biology. AI sparks bold ideas, but biology grounds them in reality. Together, they unlock solutions to humanity’s toughest health challenges, from chronic pain to addiction and beyond. Our platform embodies this synergy, combining high-throughput screening with AI-driven precision to deliver experimentally validated hits ready to transform lives. By uniting these forces, we’re not just chasing dreams, we’re building a pipeline of scalable, real world solutions. Neomera is proving that when AI and biology tango, the possibilities for better health are limitless.